Investor Relations
Nyhetsarkiv
FDA grants Paccal® Vet Minor Use designation for mammary tumors
January 16 2012Further reading »
Interim report May 1 - October 31 2011
December 8 2011Further reading »
Publication of change in the total number of shares and votes in Oasmia
October 31 2011Further reading »
Directed new share issue successfully completed – nxt2b new major shareholder
October 25 2011Further reading »
Oasmia announces launch of private placement of new shares
October 24 2011Further reading »
Enrolment complete in Phase III study with Paclical®
October 3 2011Further reading »
Communiqué from Annual General Meeting 2011
September 30 2011Further reading »
Dr. Kalliwoda Research GmbH presents a new analysis of Oasmia Pharmaceutical AB
September 15 2011Further reading »
Interim report May 1 - July 31 2011
September 8 2011Further reading »
Notice of the Annual General Meeting 2011
August 31 2011Further reading »
The Nomination Committee’s proposal regarding Board members in Oasmia Pharmaceutical AB
August 31 2011Further reading »
Oasmia publishes the annual report for the fiscal year 2010/2011
August 25 2011Further reading »
Oasmia and Orion Corporation jointly end Paclical® agreement
August 3 2011Further reading »
Positive Phase III result from the interim analysis of the study in ovarian cancer with Paclical®
August 1 2011Further reading »
Analysis from ECOFIN Global Consulting
June 28 2011Further reading »
FDA grants Paccal® Vet Minor Use designation for squamous cell carcinoma
June 13 2011Further reading »
Year-end report May 1 2010 - April 30 2011
June 10 2011Further reading »
Clinical study with Doxophos® Vet approved
June 9 2011Further reading »
Oasmia Pharmaceutical AB, Sweden and Medison Pharma, Israel announce license and distribution agreement for Paclical® in Israel and Turkey
May 12 2011Further reading »
Interim report May 1 2010 - Jan. 31 2011
March 9 2011Further reading »
Oasmia S.A. offers background and facts in response to accusations in the media
March 8 2011Further reading »
Oasmia Pharmaceutical AB announces agreement with Baxter Oncology GmbH for large scale commercial manufacturing
March 2 2011Further reading »
Björn Björnsson new Chairman of the Board of Oasmia Pharmaceutical AB
February 8 2011Further reading »
Ticker: Clarification regarding Oasmia SA
February 4 2011Further reading »
Oasmia Pharmaceutical AB:s listing on the Frankfurt Stock Exchange approved
January 21 2011Further reading »
Oasmia Pharmaceutical AB, Sweden has applied for listing at Frankfurt Stock Exchange
January 18 2011Further reading »
Publication of change in the total number of shares and votes in Oasmia
December 30 2010Further reading »
Interim report May 1 - Oct 31 2010
December 9 2010Further reading »
Oasmia Pharmaceutical completes rights issue of SEK 238.7 million
November 25 2010Further reading »
Prospectus regarding Oasmia Pharmaceutical's rights issue is now available
November 1 2010Further reading »
Oasmia Pharmaceutical AB announces a fully committed and underwritten rights issue of SEK 239 million
October 19 2010Further reading »
Communiqué from Annual General Meeting 2010
September 29 2010Further reading »
Interim report May 1 - July 31 2010
September 9 2010Further reading »
Oasmia Pharmaceutical begins the centralized approval procedure for Paccal® Vet with the EMA
August 31 2010Further reading »
Oasmia: Clinical study shows good tolerance for Doxophos® Vet
August 30 2010Further reading »
Two thirds of the patients enrolled in the Paclical® Phase III study
August 17 2010Further reading »
Paccal Vet´s Phase III study submitted to FDA for evaluation of clinical efficacy and safety
August 4 2010Further reading »
Oasmia Sweden enters into SEK 75 million Standby Equity Distribution Agreement with U.S.-based YA Global Master SPV Ltd.
July 22 2010Further reading »
The Oasmia Pharmaceutical share is now traded on NASDAQ OMX Stockholm
June 24 2010Further reading »
Oasmia is admitted to trading on NASDAQ OMX Stockholm
June 17 2010Further reading »
Oasmia Pharmaceutical appoints Remium as liquidity provider and financial advisor
June 10 2010Further reading »
Year-end report May 1 2009 - April 30 2010
June 10 2010Further reading »
Preliminary analysis indicates that Oasmia's product candidate Paccal® Vet met primary endpoint in Phase III study in dogs with mastocytoma
May 4 2010Further reading »
Björn Björnsson nominated as new Member of the Board in Oasmia Pharmaceutical AB
May 3 2010Further reading »
Oasmia closes agreement with Nippon Zenyaku Kogyo.
April 22 2010Further reading »
Last patient out (LPO) for Paccal® Vet Phase III study
March 1 2010Further reading »
Interim report May 1, 2009 - January 31, 2010
February 26 2010Further reading »
Oasmia changes report publication date
December 28 2009Further reading »
Oasmia publishes Interim Report for May - Oct
December 10 2009Further reading »
Oasmia initiates clinical studies with the new pharmaceutical candidate Doxophos® Vet for treatment of cancer in dogs.
December 9 2009Further reading »
Oasmia Pharmaceutical AB, Uppsala, Sweden, carries out private placement
November 5 2009Further reading »
Oasmia Successfully Concludes Enrolment for Pivotal Study of Mast Cell Tumors in Dogs
October 21 2009Further reading »
Communiqué from Annual General Meeting
September 28 2009Further reading »
Interim report May 1 - July 31 2009
September 10 2009Further reading »
Oasmia’s rights issue fully subscribed
August 28 2009Further reading »
OASMIA PHARMACEUTICAL AB (publ.) Notice of Annual General Meeting 2009
August 27 2009Further reading »
Oasmia S.A.’s commitment to subscribe for shares in Oasmia Pharmaceutical AB’s (publ) rights issue
August 25 2009Further reading »
The prospectus for Oasmia's new share issue 2009 is now available
August 3 2009Further reading »
Oasmia Pharmaceutical, Sweden, announces distribution agreement with Abbott Laboratories for Paccal® Vet on the US and Canadian veterinary market.
July 13 2009Further reading »
Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal® Vet, a New Chemotherapeutic Agent for Dogs
July 10 2009Further reading »
Oasmia proposes new share issue
June 24 2009Further reading »
Oasmia: FDA grants Paclical® Orphan Drug Designation for ovarian cancer in the USA
April 14 2009Further reading »
Oasmia: FDA grants Paccal® Vet Minor Use status
April 1 2009Further reading »
Interim report May 2008 - January 2009
March 19 2009Further reading »
Oasmia Pharmaceutical's international multicentre Phase III study on ovarian cancer generates great interest across Europe
February 11 2009Further reading »
Oasmia Pharmaceutical aims for worldwide registration with a pivotal study on Paccal® Vet
February 5 2009Further reading »
Communiqué from Extraordinary General Meeting
February 2 2009Further reading »
Oasmia Pharmaceutical candidate Paclical® shows promising results in patients with severe cancer.
January 27 2009Further reading »
Solid scientific evidence for Oasmia product candidate Paccal® Vet
January 21 2009Further reading »
FDA grants Oasmia Pharmaceutical Expedited Review Status (ERS) for Paclical® Vet
January 14 2009Further reading »
OASMIA PHARMACEUTICAL AB (publ.) CALL TO EXTRAORDINARY GENERAL MEETING
January 12 2009Further reading »
Oasmia appoints E. Öhman J:or Fondkommission AB as market maker and financial advisor as well as forwards the publication of the interim report
December 1 2008Further reading »
Oasmia changes marketplace
October 1 2008Further reading »
Notice of Annual General Meeting
August 14 2008Further reading »
Oasmia expands license agreement for Paclical® Vet to include European-wide rights
June 25 2008Further reading »
Oasmia enters new important license agreement for Paclical® Vet with Orion Corporation
March 26 2008Further reading »
Convincing results for Oasmia's Cancer Candidate Paclical® Vet
March 3 2008Further reading »
Oasmia presents Phase III results for Paclical® Vet in Copenhagen
January 31 2008Further reading »
EMEA final advice for start of Oasmia's Paclical® Phase III program
January 29 2008Further reading »
Oasmia Pharmaceutical announces licensing agreement with Orion Corporation regarding new innovative ovarian cancer drug candidate, Paclical®.
November 27 2007Further reading »
American veterinarians see the future in drug candidate Paclical® Vet
November 5 2007Further reading »
Oasmia's cancer drug one step closer the American market
October 9 2007Further reading »
A big step for Oasmia in Barcelona
September 27 2007Further reading »
Great interest for Oasmia in Budapest
September 20 2007Further reading »
Oasmia to NGM Equity
September 17 2007Further reading »
Oasmia publishes Listing Prospectus
September 17 2007Further reading »
Oasmia presents Paclical® Vet in Budapest
June 19 2007Further reading »
Status – listing of Oasmia
May 29 2007Further reading »
Very good clinical results for Paclical®
April 16 2007Further reading »
Unique results for cancer drug presented in Cambridge
March 27 2007Further reading »
New drug for treatment of cancer in dog
March 13 2007Further reading »
OASMIA CONFIRMS ORPHAN DRUG DESIGNATION FOR OAS-PAC-100 (PACLITAXEL MICELLAR)
November 30 2006Further reading »
OASMIA OBTAINS ORPHAN DRUG DESIGNATION FOR OAS-PAC-100 (PACLITAXEL MICELLAR)
November 15 2006Further reading »
